Articles By Anuja Singh
AI’s R&D Acceleration in Biopharma: Proven Power or Selective Promise?
AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…
ByAgentic AI in Biopharma R&D: From Hype to Hierarchical Autonomy
Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…
How Are Biopharma Giants Deploying Agentic AI to Revolutionize R&D Over the Next 5…
This executive update expands on majors like Lilly, BMS, Pfizer, GSK, Novo, plus Roche, Merck, Sanofi, and AstraZeneca,…
What If HER2 Resistance Was Over? Henlius Doses First Patient in Phase 2/3 HLX22…
Shanghai, China – March 3, 2026 – Henlius Biotech, Inc. (HKEX: 2696), a global biopharmaceutical leader in oncology innovation,…
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for CC-1234, its next-generation…
Atrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following Novartis’ $12 billion…
AI’s R&D Acceleration in Biopharma: Proven Power or Selective Promise?
AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…
Agentic AI in Biopharma R&D: From Hype to Hierarchical Autonomy
Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…
How Are Biopharma Giants Deploying Agentic AI to Revolutionize R&D Over the Next 5…
This executive update expands on majors like Lilly, BMS, Pfizer, GSK, Novo, plus Roche, Merck, Sanofi, and AstraZeneca,…
What If HER2 Resistance Was Over? Henlius Doses First Patient in Phase 2/3 HLX22…
Shanghai, China – March 3, 2026 – Henlius Biotech, Inc. (HKEX: 2696), a global biopharmaceutical leader in oncology innovation,…
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for CC-1234, its next-generation…
Atrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following Novartis’ $12 billion…